A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Deferasirox (Primary) ; Deferasirox
- Indications Iron overload
- Focus Therapeutic Use
- Sponsors Novartis
- 27 Jul 2017 Planned End Date changed from 29 Dec 2023 to 29 Mar 2024.
- 27 Jul 2017 Planned primary completion date changed from 29 Dec 2023 to 29 Mar 2024.
- 10 Jun 2017 Biomarkers information updated